Screener
Alamar Biosciences ALMR Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payment of deferred offering costs | (2,218) | — |
| Net cash provided by financing activities | 55,761 | 243 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | (52) | 133 |
| Net increase in cash, cash equivalents and restricted cash | 34,584 | 4,326 |
| Cash, cash equivalents and restricted cash at beginning of period | 34,909 | 31,677 |
| Cash, cash equivalents and restricted cash at end of period | $69,493 | $36,003 |
| Supplemental disclosure of cash-flow information: | ||
| Cash paid for interest | $156 | $3 |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's net change in cash?
- Alamar Biosciences (ALMR) reported net change in cash of $34.58M in Q1 2026.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Alamar Biosciences's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude